Detailed Narrative
Sun Pharmaceutical Industries concluded FY25 with a strong financial performance, reporting full year sales of Rs. 520,412 million, a 9% increase over the previous year. This growth translated into a significant 17.3% rise in EBITDA to Rs. 152,717 million, with the EBITDA margin expanding to 29%. Adjusted net profit for the full year also saw a healthy 19% increase, reaching Rs. 119,844 million. For the fourth quarter of FY25, sales grew 8.5% to Rs. 128,156 million, and EBITDA increased 22.4% to Rs. 37,161 million, achieving a margin of 28.7%. Adjusted net profit for Q4, excluding exceptional item📎s, was Rs. 28,890 million, up 4.8%.
The India formulation business was a key growth driver, achieving Rs. 169,230 million in sales for FY25, a 13.7% increase, and Rs. 42,130 million in Q4, up 13.6%. The company maintained its number one ranking in the Indian pharmaceutical market with an 8.3% market share. The Global Specialty business also performed robustly, with FY25 sales reaching $1,216 million, a 17.1% increase, and Q4 sales at $295 million, up 8.6%. Key specialty products like ILUMYA, CEQUA, WINLEVI, and ODOMZO contributed significantly to this growth. Emerging markets also showed solid performance, with full year revenues of $1,114 million (up 7%) and Q4 revenues of $261 million (up 6.3%, or 11.5% in constant currency).
Management provided a positive outlook for FY26, guiding for "mid to high single digit consolidated topline growth." The company plans to invest an additional "approximately US$ 100 million" in FY26 for the commercialization of new Specialty products, viewing this as a strategic investment to strengthen the business. R&D spend for FY26 is projected to be "6% to 8% of sales." A significant product launch, Leqselvi, is anticipated in Q2 FY26 in the US, despite ongoing patent litigation. The company also announced the acquisition of Checkpoint Therapeutics to leverage UNLOXCYT in targeted oncology.
During the Q&A, management addressed concerns regarding the US generic business decline due to competition and pricing pressure, attributing it to product-specific issues. They also discussed the potential impact of new MFN laws, noting a lack of clarity on implementation, and the long timeline (2.5-3 years) and high cost associated with establishing new US-based manufacturing for biologics like Ilumya. The effective tax rate is expected to "continue to go up" in FY26 due to the exhaustion of tax losses. Overall, the management expressed confidence in their strategic direction and pipeline, while acknowledging external uncertainties.